Lancet data support Amgen's PCSK9 inhibitor as race hots up
This article was originally published in Scrip
As the race to be first to market with a PCSK9 inhibitor reaches its final, tense stages, one competitor, Amgen, has published the results of two of its pivotal trials for its offering evolocumab in The Lancet.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.